MaxCyte buys into CAR-T with Johns Hopkins partnership

Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program. The two plan to develop treatments that rewire patients' own immune cells to better detect and attack cancer, outfitting T cells with chimeric antigen receptors, or CARs. CAR-T therapies have thus far demonstrated excellent early results in blood cancers, and, building on that principle, MaxCyte and JHU are targeting solid tumors with their research. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.